Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) (Q33854032)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) |
scientific article |
Statements
1 reference
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) (English)
1 reference
J Shaw
1 reference
M Brändle
1 reference
W M W Bebakar
1 reference
N A Kamaruddin
1 reference
J Strand
1 reference
M Zdravkovic
1 reference
T D Le Thi
1 reference
LEAD-1 SU study group
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference